The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

The Food and Drug Administration (FDA) has granted accelerated approval to Tecvayli ™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who ...

The Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) who have ...

Background: Heavily pretreated patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with standard of care therapy have median overall survival (OS) of ~12 months (mo). In the single ...

In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 patients receiving ciltacabtagene autoleucel, or cilta-cel, for the treatment of relapsed or ...

Background: Patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) still need more and better treatment options. CN201 is a novel CD19-targeting T-cell-engaging IgG4 ...

The trial, conducted at MD Anderson Cancer Center between June 2014 and March 2019, was a single-arm open-label trial that enrolled 66 patients with relapsed or refractory follicular lymphoma (FL ...

Researchers sought to determine whether salvage high-dose chemotherapy plus ASCT would be effective for patients with relapsed/refractory MM.